In this review, the Authors assess the current evidence, make clinical considerations, and propose future directions for treatment de-escalation and discontinuation in MOGAD and AQP4-Ab NMOSD, including specific consideration in pediatric population.
See the full manuscript here: https://www.neurology.org/doi/10.1212/WNL.0000000000218482